US FDA awards priority review for Sucampo/Takeda constipation drug
This article was originally published in Scrip
Executive Summary
Sucampo and Takeda won a six-month priority review for their supplemental new drug application (sNDA) for Amitiza (lubiprostone) as a treatment for opioid-induced constipation (OIC) in patients with chronic, non-cancer pain, with the US FDA expected to make a decision on the drug by late January.